Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma Clinical Trial

Official title:

Feasibility of Low Dose Radiation as Bridging Therapy for Lisocabtagene Maraleucel in Relapsed B-Cell Non-Hodgkin Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05621096
• Other study ID #: 0770-22-FB
• Status: Recruiting
• Phase: Phase 1
• Start date: March 21, 2023
• Est. completion date: July 2025

Study information

• Verified date: September 2023
• Source: University of Nebraska
• Contact: Maribeth A Hohenstein, RN
• Phone: 402-559-9053
• Email: mahohens[@]unmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions:

• If it is realistic to give people radiation treatment before they receive a chimeric antigen receptor (CAR) T-cell treatment for their cancer

• If it is safe to give people radiation treatment before they receive a CAR T-cell treatment for their cancer

Description:

This is a pilot study to evaluate the feasibility of low-dose radiation therapy in the bridging period between chimeric antigen receptor (CAR) T-cell collection, manufacturing, and infusion (vein-to-vein) in patients with relapsed and refractory aggressive B-cell lymphoma.

Emerging cellular immunotherapies including CAR T-cell therapy have produced remarkable outcomes for this population. The Food and Drug Administration (FDA) has recently approved lisocabtagene maraleucel (liso-cel) for the management of people with relapsed and refractory B-cell lymphoma. Unfortunately, many patients undergoing liso-cel infusion will suffer progression or relapse with devastating consequences. The object of this study is to identify a novel means to enhance liso-cel activity to improve overall outcomes. The investigators hypothesize that the addition of radiation therapy targeting selected sites as bridging therapy prior to lymphodepleting chemotherapy and liso-cel infusion will be effective at improving responses for patients with relapsed and refractory B-cell lymphoma.

Results from this study will provide key justification to expand this therapeutic approach into a larger phase II clinical trial powered to examine the efficacy of this approach.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 33
• Est. completion date: July 2025
• Est. primary completion date: July 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Biopsy-proven relapsed or progressive diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, grade 3B follicular lymphoma, or DLBCL arising from indolent lymphoma meeting an FDA-approved (Food and Drug Administration-approved) indication for liso-cel infusion

2. Presence of disease on imaging including at least one disease site safe for radiation as determined by treating radiation oncologist

3. Willingness to participate in clinical trial and provide informed consent

4. Adequate organ function as assessed by standard institution protocols and United States (US) prescribing information label for comorbidities, heart, and lung function to undergo FDA-approved CAR T-cell therapy as determined by institution

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

6. Age 19 years or older, there is no upper limit to the age

Exclusion Criteria:

1. Subject is unsafe for radiation therapy as determined by investigator and/or radiation oncologist

2. Diagnosis is primary central nervous system (CNS) lymphoma (secondary CNS lymphoma with additional systemic site is allowed)

3. Requirement for concurrent high dose methotrexate

4. Secondary active malignancy that has not been in remission for at least 2 years. This excludes non-melanoma skin cancer, definitively treated stage 1 solid tumor with low risk or recurrence, and curatively treated localized prostate cancer.

5. Pregnant or nursing women

6. Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as determined by investigator

7. Unwillingness to follow procedures required in the protocol

8. Inadequate organ or hematologic conditions that prohibit the use of lymphodepleting chemotherapy

9. Use of lymphoma-directed therapy within 14 days of T-cell pheresis

Related Conditions & MeSH terms

• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Indolent B-Cell Non-Hodgkin Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Non-Hodgkin
• Mediastinal Large B-cell Lymphoma
• Refractory Non-Hodgkin Lymphoma
• Relapsed Non-Hodgkin Lymphoma

Intervention

Radiation:
• Bridging radiation therapy
Days -20 to -7: Patients will receive 2 fractions of 2 gray (Gy) for a total of 4 Gy received.

Biological:
• Liso-cel
Day 0: Patients will receive an infusion of liso-cel CAR T-cell product. Prior to the liso-cell infusion (Days -5 to -3), patients will receive lymphodepleting chemotherapy using fludarabine 30mg/m2 and cyclophosphamide 300mg/m2 per institutional standard procedures.

Radiation:
• Post-infusion radiation
Days 30 to 80: Patients eligible for post-infusion radiation will receive a total dose of up to 32 Gy.

Locations

Country	Name	City	State
United States	University of Nebraska Medical Center	Omaha	Nebraska

Sponsors (2)

Lead Sponsor	Collaborator
University of Nebraska	Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Prospectively bank serum and peripheral blood mononuclear cells (PBMCs)	Storage for subsequent correlative analyses in future research. No analysis plan is provided.	Up to 270 days
Other	Prospectively bank stool samples for future gut microbiome exploratory analyses	Sample storage at indicated timepoints. No specific analysis is intended on this protocol	Up to 270 days
Other	Evaluate in-field versus out-of-field disease progression following radiation therapy	Proportion of individual disease sites with local progression by Lugano criteria defined by within the treated radiation field versus outside the treated radiation field	Up to 270 days
Primary	Feasibility of the intervention in the proposed study population	The percentage of subjects who receive a chimeric antigen receptor (CAR) T-cell infusion after receiving bridging radiation therapy. A one-sided Binomial test will be conducted to assess whether acceptable percentage (>70% vs <70%) of patients receive CAR T-cell perfusion after undergoing the radiation therapy.	Up to 90 days
Secondary	Incidence of treatment-emergent adverse events to assess the safety of the proposed intervention	Assessed via the incidence of combined Grade 3 and 4 cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity syndrome (ICANS) events as measured by the American Society of Transplant and Cellular Therapy (ASTCT) consensus grading. The grading scale ranges from Grade 1 to 4, with a higher grade indicating a worse outcome. Assessed from the cumulative CRS and ICANS events occurring by the D+30 visit.	Up to 120 days
Secondary	Evaluate the response to the study intervention of radiation and CAR T-cell therapy	Response rate will be assessed via PET/CT (positron emission tomography/computed tomography) using Lugano criteria. Overall response rate (ORR) will be defined as the proportion of patients with either a complete response (CR) or a partial response (PR) at D+100. For ORR, CR, and PR: two-sided exact binomial 95% confidence interval of response rate will be constructed to assess the precision of the point estimate.	Up to 190 days
Secondary	Evaluate progression-free survival (PFS) following the study intervention	PFS will be measured using the Kaplan-Meier method. Disease progression will be measured according to clinical and imaging assessment (Lugano criteria) and will require biopsy confirmation.	Measured from first day of apheresis to death or disease progression, whichever comes first, up to two years
Secondary	Evaluate duration of response (DOR) following CAR T-cell therapy	DOR will be summarized using the Kaplan-Meier method, but only for patients who have achieved a response of at least partial response. DOR is defined by time of first response (D+30 visit) to disease progression, start of new antineoplastic therapy due to efficacy concerns, or death from any cause.	Up to 2 years
Secondary	Evaluate overall survival (OS) following study intervention	OS will be analyzed by the Kaplan-Meier method. Subjects alive at last follow up will be censored.	Up to 2 years
Secondary	Evaluate the rate of prolonged cytopenias following the intervention	The rate of prolonged cytopenias will be measured as a proportion of subjects with Grade 3 or higher hematologic toxicities per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria at the D+100 visit. The 95% confidence interval will be estimated.; The CTCAE v5.0 grading system ranges from Grade 0 to 5, with a higher grade indicating a worse outcome.	Up to 190 days
Secondary	Monitor overall safety and toxicity of the intervention	Toxicity will be graded using CTCAE v5.0 guidelines. Grade 3 or higher toxicities will be tabulated using percentages at each follow up. The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading system ranges from Grade 0 to 5, with a higher grade indicating a worse outcome.	Up to 270 days
Secondary	Monitor Cytokine release syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS) toxicity events	Cytokine release syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS) toxicity events will be collected for all grades as measured by American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria.; The ASTCT consensus criteria grading system ranges from Grade 1 to 4, with a higher grade indicating a worse outcome.	Up to 270 days